Remimazolam for successful sedation in children with left-to-right shunt congenital heart disease

作者：Ming Jin, Hongqi Lin, Lin Qiu, Hongdang Xu, Haoran Zhang, Shuhui Hou · 发表于：European Journal of Anaesthesiology · 年份：2025 · DOI：10.1097/eja.0000000000002183 · 被引用次数：7 · 研究领域：Congenital Heart Disease Studies、Cardiovascular Conditions and Treatments、Neonatal Respiratory Health Research

BACKGROUND: The findings of this study offer insights into the utilisation of remimazolam for sedation in paediatric patients with left-to-right shunt congenital heart disease (CHD). OBJECTIVE: To study the median effective dose (ED 50 ) and 95 percentile of the effective dose (ED 95 ) of remimazolam for successful sedation in children with CHD. DESIGN: A nonrandomised, nonblinded study based on the Dixon sequential method. SETTING: Tertiary hospitals in Zhengzhou, Henan Province, study dates: 20 October 2023 to 18 May 2024. PATIENTS: A total of 78 patients, comprising 32 males and 45 females, successfully completed the study. They were selected based on the following criteria: children aged 1 to 6 years with left-to-right shunt CHD; ASA physical status II-III. The key exclusion criteria were: history of allergy to sedative drugs; administration of sedative medications other than the study drug before surgery; severe pre-operative liver or kidney dysfunction; pre-operative bradycardia; and severe pre-operative respiratory diseases. INTERVENTION: The sedation status of the patients was observed for 5 min after intravenous administration of different doses of remimazolam. MAIN OUTCOME MEASURES: The ED 50 and ED 95 of remimazolam for successful sedation in children with CHD. RESULTS: The ED 50 (95% CI) of remimazolam for successful sedation in infants, toddlers and preschool children with CHD were 0.209 (0.184 to 0.234) mg kg -1 , 0.259 (0.234 to 0.284) mg kg -1 and 0.266 (0.207...